

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES
EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39173 I-MAB 2440
Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark
whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F
Form 40-F Costs Associated with Exit or Disposal
Activities On January 28, 2025, I-MAB (the Company or I-Mab) completed a workforce reduction
designed to right size the organization and realign the Company's clinical development support as a result of the
Company's recently announced pipeline reprioritization (the Realignment Plan). The Realignment Plan
reduced the Company's workforce by approximately 27%. The Company currently estimates that it will incur one-
time cash charges associated with the Realignment Plan of approximately \$0.8 million primarily related to employee
severance payments, benefits and related termination costs. The Realignment Plan is expected to result in annual
operating expense savings of approximately \$3.0 million. The Company expects that the Realignment Plan will be
substantially complete with the majority of related charges recognized in the first quarter of 2025. The estimates of the
charges and expenditures that the Company expects to incur in connection with the Realignment Plan, and the timing
thereof, are subject to several assumptions and the actual amounts incurred may differ materially from these estimates.
In addition, the Company may incur other charges or cash expenditures not currently contemplated due to
unanticipated events that may occur, including in connection with the implementation of the workforce reduction.
Forward Looking Statements This current report on Form 6-K (the Report) contains forward-looking statements.
These statements are made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act
of 1995. These forward-looking statements can be identified by terminology such as will, expects, believes, designed to, anticipates, future, intends, plans, potential, estimates, confidential, and similar terms or the negative thereof. Statements that are not historical facts,
including statements about I-Mab's beliefs and expectations, are forward-looking statements. Forward-looking
statements in this Report include statements regarding: expectations related to the Realignment Plan, including
estimated costs, charges and expenditures, impairments and the timing and financial impacts thereof; and the
Company's expectations with respect to operational efficiencies and reduction of expenditures. Forward-looking
statements involve inherent risks and uncertainties that may cause actual results to differ materially from those
contained in these forward-looking statements, including: I-Mab's ability to demonstrate the safety and efficacy of
its drug candidates; the clinical results for its drug candidates, which may or may not support further development or
New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by
the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to
achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of
intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development,
manufacturing and other services; and I-Mab's limited operating history and I-Mab's ability to obtain additional
funding for operations and to complete the development and commercialization of its drug candidates, as well as those
risks more fully discussed in the Risk Factors section in I-Mab's most recent annual report on Form 20-F, as
well as discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with
the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no
obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future
events, or otherwise, except as may be required by law. Incorporation by Reference This Report shall be deemed to be
incorporated by reference into the registration statements on Form S-8 (File No. 333-279842, File No. 333-265684, File
No. 333-256603 and File No. 333-239871) of the Company (including any prospectuses forming a part of such
registration statements) and to be a part thereof from the date on which this Report is furnished, to the extent not
superseded by documents or reports subsequently filed or furnished. SIGNATURES Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized. I-MAB By : /s/ Joseph Skelton Name : Joseph
Skelton Title : Chief Financial Officer Date: January 29, 2025